(Reuters) - U.S. specialty drugmaker Allergan Inc said late on Tuesday that it would buy MAP Pharmaceuticals Inc for about $958 million in cash, an acquisition intended to widen its presence in the treatment of adult migraines.https://mf.feeds.reuters.com/c/871/f/...7cc308c/mf.gif
https://da.feedsportal.com/r/15188473...7cc308c/a2.imghttps://pi.feedsportal.com/r/15188473...cc308c/a2t.img
More...
